Oppenheimer downgraded Insulet Corporation from Outperform to Perform following the company's strong Q2 earnings report, which showed 23% revenue growth and improved profitability metrics. Despite the solid quarterly results driven by demand for its Omnipod insulin-delivery system, Insulet lowered its full-year revenue growth forecast for U.S. and total operations. This revised outlook led to a negative market reaction, with the stock dropping over 20% to a 52-week low. Investors are now cautious as the company adjusts expectations for the remainder of 2026.
Evercore ISI increased its price target for Shopify to $175, reflecting an 18.51% potential upside following the company's strong Q2 results. Shopify reported a 34% revenue increase to $3.6 billion and an EPS of $0.42, beating estimates. Key growth d...
TAT Technologies Ltd. reported quarterly earnings of $0.35 per share, beating analyst estimates by 25%, driven by robust aerospace demand and a record $615 million backlog. Revenue rose 22.8% year-over-year to $52.94 million, surpassing expectations ...
SenesTech reported significant growth in Q2 2026 with its online subscriber base more than doubling and e-commerce revenue rising 186% from Q1. Despite this growth, the company expects an EPS loss of $0.37 on revenues around $601,500, reflecting ongo...
Concentrix and Currys have won the NiCE 2026 International CX Excellence Award for their innovative transformation of customer engagement using NiCE CXone technology. This solution unified customer interactions across all channels, improving satisfac...
Concentrix and Currys received the 2026 NiCE International CX Excellence Award for their innovative use of technology to enhance customer engagement. By implementing NiCE CXone, they unified customer interactions across multiple channels, improving s...
